Selecting selectins for psoriasis

While two new biotech products developed to treat psoriasis are expected to be under regulatory review this year, all the products in development for the indication are injectable. Last week a group of researchers published the identification of a new class of compounds that use a similar mechanism to one of the products in development, but which might be orally active.

Researchers from Wolfgang-Goethe University in Frankfurt and colleagues published in Nature Medicine the identification and synthesis of a new class of macrolides, called efomycines, that mimic the three-dimensional structure of endogenous selectin ligands...